Gilead Knew Hepatitis Drug Price Was High, Senate Says

Gilead Sciences knew the $1,000-a-pill launch price for its hepatitis treatment would be out of reach for many patients, a Senate report concluded Tuesday.

from WSJ.com: US Business http://ift.tt/1IBQ0Rw
via IFTTT